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ABSTRACT
Glucocorticoids are widely used in threatened preterm labor to promote maturation in many organ
systems in preterm babies and have signiﬁcant beneﬁcial effects on morbidity and mortality. We
performed transcriptional proﬁling in fetal liver in a rat model of prenatal glucocorticoid exposure and
identiﬁed marked gene expression changes in heme biosynthesis, utilization, and degradation pathways
in late gestation. These changes in gene expression associated with alterations in DNA methylation and
with a reduction in hepatic heme concentration. There were no persistent differences in gene expression,
DNA methylation, or heme concentrations at 4 weeks of age, suggesting that these are transient effects.
Our ﬁndings are consistent with glucocorticoid-induced accelerated maturation of the haematopoietic
system and support the hypothesis that glucocorticoids can drive changes in gene expression in
association with alterations in DNA methylation.
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Introduction
The ability of glucocorticoids to function as promoters of
maturation in organ systems is widely exploited pharmaco-
logically as a treatment for women with threatened preterm
labor with signiﬁcant beneﬁcial effects on morbidity and
mortality in babies born preterm.1 The major reason under-
pinning the use of antenatal glucocorticoids is to enhance
lung maturation,1 and glucocorticoids induce the expression
of genes involved in many processes in the developing lung,
including the synthesis of surfactant proteins.2,3 However,
glucocorticoids are also known to stimulate maturation in
many other differentiating tissues, including the liver, pan-
creas, kidney, and heart.4
In order to understand the mechanisms by which gluco-
corticoids affect fetal development and maturation, a num-
ber of animal models have been developed.5 Using one such
model, in which pregnant rat dams are treated with the
synthetic glucocorticoid Dexamethasone (Dex) during the
last week of pregnancy, we have previously shown that pre-
natal glucocorticoid overexposure alters the expression of
candidate genes in fetal liver.6-8 In this study, we set out to
identify additional pathways that are affected by prenatal
glucocorticoid exposure by performing transcriptional pro-
ﬁling in late gestation fetal liver at embryonic day (e)20
from prenatally glucocorticoid-exposed rats. To determine
whether changes were persistent, we also analyzed candidate
gene expression in liver at 4 weeks of age. Since a growing
number of studies, including in this model, suggest that
early life exposure to glucocorticoid excess may drive
changes in gene expression through alterations in the
epigenome, particularly DNA methylation changes,6,9,10 we
additionally performed analysis of DNA methylation at pro-
moters of differentially expressed candidate genes.
Results
Dex-exposed males exhibit transcriptional changes in the
liver heme pathway at e20
A total of 134 genes were differentially expressed between Dex
and Veh male liver (P < 0.01 and a difference of 10% or
greater). Pathway analysis using the GeneGo tool revealed
marked gene expression changes in heme biosynthesis, utiliza-
tion, and degradation pathways (Supplementary Fig. 1A and
B). Quantitative PCR validation conﬁrmed that Dex exposure
was associated with decreased expression of 4 genes involved
in the heme biosynthesis pathway (Alad: 1.9-fold, P D 0.005,
Cpox: 2-fold, P D 0.0006, and Urod: 1.9-fold, P D 0.0001, and
the rate-limiting enzyme Alas2: 1.4-fold, P D 0.03) (Fig. 1A).
Dex exposure also decreased the expression of Biliverdin
reductase B (Blvrb), which is involved in heme degradation
(1.7 fold, P D 0.001) (Fig. 1A). In contrast, Dex exposure was
associated with increased expression of mRNA encoding the
heme-containing cytochrome P450 2C23 enzyme (Cyp2c23:
1.9-fold, P D 0.003) (Fig. 1A). The experiment was not
designed to analyze the changes in gene expression over time
so we are unable to compare pre- and post-natal gene expres-
sion directly. However, none of the expression changes identi-
ﬁed at e20 was maintained at 4 weeks of age, although we
identiﬁed increased expression of Hmbs postnatally (Fig. 1B).
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DNA methylation changes in alternative promoters
of Hmbs and Alad may facilitate expression differences
at e20
Two genes in the heme synthesis pathway, Alad and Hmbs,
have erythroid-speciﬁc and housekeeping isoforms, the
expression of which are driven from different promoters.
Given the changes in Alad gene expression at e20, we pro-
ceeded to analyze DNA methylation at the alternate pro-
moters of both genes. The housekeeping promoters for both
Alad and Hmbs are constitutively unmethylated, and there
was no difference in methylation levels between the two
Figure 1. Prenatal glucocorticoid overexposure is associated with altered expression of genes in the heme pathway at embryonic day (e)20 but not at 4 weeks. A) Gene
expression at e20. B) Gene expression at 4 weeks. nD8 per group at each time point. Data are mean § SEM. P < 0.05, P < 0.01.
Table 1. Primer details for qPCR and pyrosequencing analysis.
qPCR analysis
Gene Forward Reverse UPL probe
Alas2 caggggctttcctgttatcc tgttgagtgccgcattacc 5
Cpox gtcctgaagcacacaggtga tctgccctctggttttctgt 10
Urod ttagcaatgtagcgctgtgg tctaggaagagattggtcgactg 84
Alad gcctttgatctcaggactgc ggggtgcaaagtaggtgatg 109
Hmbs tccctgaaggatgtgcctac acaagggttttcccgtttg 79
Cyp2c23 ccctcgggactacattgact gatggaactcagacttcaggttg 63
Pyrosequencing
Gene Forward Reverse Sequencing
Alad P1 gtttagaagggagtgtaggttgta ctaccaaaaaccctactcaccacc ggagtgtaggttgtatttt
Alad P2 ttgagatagggttggttttgaatt ccccacaaaaactctataactaacc ggatgattatggatttttga
Alad GB ataagtggaagtttggggaaat attaatacactcaccatcctaatca caaaaacaaacaaattaaacaatat
Hmbs P1 ggttttttggagtttgtagaag aactcccaccccatataccttcaat tttggagtttgtagaagt
Hmbs P2 tgagtgggagggttgtata atctatcctaccccaacctct aatgataaggtttattagttttaag
Hmbs GB aggtagaataagtgggaagtagaa tcaataccattatcctaactataactaacc gggaagtagaataggg
Cyp2c23 P1 aggggaagtattttttgtataggtat tccccactttaaaacacattccttatt agtattttttgtataggtatgtt
Cyp2c23 P2 agggttaaaatggagttgttgg ccccctaatacccaattttatccacacta atggagttgttggga
Cyp2c23 GB gttagggttttgtagtgttttaagt tttccctatatcattaaaatctttct ttggataaattattatatttttttg
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groups (Table 2). In contrast, at e20, DNA methylation was
signiﬁcantly increased in Dex-exposed animals at the ery-
throid-speciﬁc promoter of both genes (Fig. 2A and B).
There were no differences in DNA methylation in the gene
body (Fig. 2C and D). There were no persistent differences
in DNA methylation at 4 weeks (Fig. 2E-H).
Dex exposure is associated with DNA methylation changes
in the Cyp2c23 promoter and gene body
Given the increase in Cyp2c23 expression at e20 we pro-
ceeded to investigate DNA methylation at the Cyp2c23 pro-
moter and gene body. At e20, Dex exposure was associated
with decreased DNA methylation at the Cyp2c23 promoter
(4 CpGs out of 6 tested), but with increased DNA
Figure 2. DNA methylation at Alad and Hmbs. Pyrosequencing analysis showed increased DNA methylation at the erythroid promoter of (A) Alad and (B) Hmbs in Dex-
exposed fetuses, and absence of any differences in DNA methylation in gene bodies of (C) Alad and (D) Hmbs gene bodies. At 4 weeks, there were no persistent differen-
ces in DNA methylation at the erythroid promoters of (E) Alad and (F) Hmbs or in the gene bodies of (G) Alad or (H) Hmbs. Data are mean § SEM. P < 0.05, P < 0.01.
Table 2. DNA methylation at the housekeeping promoters of Alad and Hmbs.
CpG1 CpG2 CpG3 CpG4
Alad Veh 0.78§ 0.16 0.93 § 0.19 0.69 § 0.13 1.36 § 0.21
Dex 0.78§ 0.18 0.94 § 0.19 0.72 § 0.14 1.08 § 0.20
Hmbs Veh 0.53§ 0.03 0.44 § 0.07 0.61 § 0.03 0.52 § 0.03
Dex 0.47§ 0.04 0.26 § 0.07 0.64 § 0.03 0.46 § 0.02
Data are expressed as % methylation§ SEM
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methylation in the Cyp2c23 gene body (Fig. 3A and B).
DNA methylation at the Cyp2c23 gene promoter decreased
between e20 and 4 weeks of age and, although DNA meth-
ylation differences present at e20 were not persistent, a new
difference emerged at a single CpG at 4 weeks (Fig. 3C). In
contrast, DNA methylation increased in the Cyp2c23 gene
body over time and there was a persistent difference in
DNA methylation at a single CpG (Fig. 3D).
Dex exposure decreases hepatic heme concentrations
at e20
In order to identify potential functional consequences of
alterations in gene expression and DNA methylation
changes in genes important in the heme pathway, we
quantiﬁed heme concentrations in the liver. At e20, Dex
exposure reduced liver heme protein content by 1.6-fold
(Veh 26.7 § 4.2 vs. Dex 16.6 § 1.7 mM/mg; P D 0.048).
While liver heme protein content was reduced in the postnatal
samples compared to e20, there were no persistent differences
between groups (Veh 10.1§0.6 vs. Dex 9.4 § 0.4 mM/mg).
Discussion
Here we have shown that prenatal glucocorticoids impact the
heme pathway in fetal liver at multiple levels with effects on
gene transcription, DNA methylation, and hepatic heme con-
tent. During mammalian development, hematopoiesis initiates
at multiple times and locations: in early development, hemato-
poiesis occurs in the yolk sac, allantois, placenta, and aorta–
gonad–mesonephros, followed by a shift to fetal liver (from day
e11–12 in mice and by 5 weeks post-conception in humans).11
In mice, hematopoiesis begins to occur in the spleen from day
e14 and in the bone marrow from e18. In humans, hematopoie-
sis moves from the fetal liver to the bone marrow at »12 weeks
post-conception. Although in postnatal life most heme synthe-
sis occurs in developing red cells in the bone marrow, the for-
mation of heme-containing enzymes, including the cytochrome
P450 enzymes, persists in the liver.12 In our study, expression
microarray and qPCR analysis of gene expression at e20
revealed that prenatal Dex was associated with decreased
expression of genes involved in heme synthesis in rat liver.
These results suggest that the transition from liver to bone mar-
row hematopoiesis is accelerated with Dex treatment; this is
supported by our ﬁndings of lower hepatic heme following Dex
exposure. These changes appear to be transient, however, since
there were no persistent differences in gene expression or
hepatic heme concentrations at 4 weeks of age.
Two of the genes involved in heme synthesis, Alad and
Hmbs, utilize alternative promoters allowing erythroid-speciﬁc
and non-erythroid regulation.12 Transcription of the full-length
isoforms is regulated by housekeeping promoters, which over-
lap CpG islands and are expressed in all tissues, whereas tissue-
speciﬁc promoters regulate transcription of the shorter iso-
forms, which are expressed only in erythroid cells.13,14 As
expected, given that they overlap CpG islands, the housekeep-
ing promoters of Alad and Hmbs were unmethylated. In con-
trast, the erythroid cell speciﬁc promoter of Alad showed
modest but signiﬁcant differences in DNA methylation, which
correlated with the observed changes in gene expression.
Although there were no signiﬁcant changes in Hmbs expres-
sion, we also observed an increase in DNA methylation at the
erythroid cell speciﬁc promoter, suggesting a shift away from
erythroid-speciﬁc expression. These differences in DNA
Figure 3. DNA methylation at Cyp2c23. Pyrosequencing analysis showed decreased DNA methylation in the (A) Cyp2c23 promoter and increased methylation in the (B)
Cyp2c23 gene body in Dex-exposed fetuses. At 4 weeks, DNA methylation was increased at a single CpG in the (C) Cyp2c23 promoter and (D) Cyp2c23 gene body in Dex-
exposed fetuses. Data are mean § SEM. P < 0.05, P < 0.01.
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methylation were not persistent at four weeks of age, at which
time DNA methylation levels were much higher than at e20,
consistent with the postnatal silencing of erythroid cell speciﬁc
promoter driven gene expression.
The peak expression of Cyp2c23 occurs around the time of
birth 15,16 so that the Dex-induced increase in expression at e20
again suggests premature maturation. Since heme is required
for incorporation into cytochrome enzymes, including
Cyp2c23 in hepatocytes, increased utilization could be an addi-
tional explanation for the decreased hepatic heme concentra-
tions at e20. The decrease in Cyp2c23 promoter DNA
methylation and increased methylation in the gene body are
consistent with the observed increase in gene expression. In
contrast to the lack of DNA methylation changes at Alad and
Hmbs at 4 weeks of age, there was a persistent difference in
DNA methylation at a single CpG in the Cyp2c23 promoter at
4 weeks and a new difference emerged at one CpG in the
Cyp2c23 gene body. Nevertheless, the signiﬁcance of these
changes at 4 weeks is unclear since there was no difference in
gene expression at this time.
Our data for the Cyp2c23 promoter, suggesting that gluco-
corticoids associate with alterations in DNA methylation that
may facilitate gene transcription are in agreement with previous
studies showing that glucocorticoids induce demethylation of
the hepatic tyrosine aminotransferase gene promoter in late
gestation, which is permissive for transcription factor binding
17 and the induction of transcription in early postnatal life in
response to hypoglycemia.18 However, glucocorticoids both
stimulate and repress gene transcription,19 so that both
decreases and increases in DNA methylation might be expected
to occur as a consequence of glucocorticoid exposure. Thus, in
contrast to the decrease in DNA methylation observed at the
Cyp2c23 promoter, increased methylation was observed in
association with repression of transcription, most notably at
the erythroid-speciﬁc promoter of Alad. Although the changes
in DNA methylation were modest, they are consistent with
other studies showing effects of the prenatal environment.20
Additionally, for Alad and Hmbs, the normal increase in DNA
methylation at the erythroid-speciﬁc promoters between e20
and 4 weeks further supports the suggestion that glucocorti-
coids induce early maturation of this pathway.
Although the main reason for antenatal glucocorticoid use
in the context of threatened preterm labor is for enhancement
of fetal lung maturation,1 glucocorticoids also stimulate matu-
ration in other tissues 4 and our study provides further evidence
for effects on the fetal liver. At around the time of birth, the
liver switches from an organ involved in hematopoiesis to one
primarily involved in metabolism, with functions including
detoxiﬁcation, regulation of glycogen storage and protein syn-
thesis. Previous studies in the model used here have shown that
prenatal glucocorticoid exposure stimulates the premature pro-
duction of the hepatic gluconeogenic enzyme phosphoenolpyr-
uvate carboxykinase, erythropoietin, and the transcription
factor HNF4a.7 Our data, suggesting that glucocorticoids also
promote early maturation of hematopoiesis, is consistent with
data from primary fetal hepatic cell culture, in which glucocor-
ticoids are associated with suppression of in vitro hematopoie-
sis.21 Taken together, these results suggest that glucocorticoid-
induced fetal hepatic maturation is associated with the
termination of hematopoiesis and the relocation of haemato-
poietic cells. These changes may be beneﬁcial in the context of
preterm birth, promoting maturation of metabolic function
and facilitating adaptation to the extrauterine environment.
There are, however, ongoing concerns about the long-term
effects of prenatal glucocorticoid overexposure, particularly
with repeated dosing.1 Our data suggest that the majority of
glucocorticoid-induced changes in gene transcription and
DNA methylation in relation to the heme pathway are not per-
sistent, at least up to 4 weeks of age. Nevertheless, there were
some persistent changes in DNA methylation in the Cyp2c23
promoter and gene body. Cyp2c enzymes epoxidise arachidonic
acid to metabolites involved in the regulation of vascular and
renal function 22 and, since prenatal glucocorticoid overexpo-
sure is associated with the development of hypertension in
adulthood,23 persistent effects on Cyp2c23 expression or DNA
methylation may deserve further investigation. Although these
persistent changes were CpG speciﬁc, previous studies have
suggested that site-speciﬁc differences in DNA methylation
may be important in mediating changes in the postnatal
phenotype.20,24,25
In conclusion, our data showing that prenatal glucocorti-
coids induce changes in gene expression and DNA methylation
at key genes in the heme biosynthesis pathway suggest a mech-
anism through which glucocorticoids associate with accelerated
maturation.
Material and methods
Animals and tissues
Pregnant female Wistar rats were injected subcutaneously with
either Dex (100 mcg/kg in 0.9% saline containing 4% ethanol)
or with equivalent volume of vehicle (Veh; 0.9% saline contain-
ing 4% ethanol) administered daily between 0800 and 0900
from e15 to e21 inclusively. Our previous studies in this model
have shown that this dose of Dex reduces birth weight without
affecting litter size or gestation length.26 A subgroup of preg-
nant females were killed at e20 (8 Dex and 8 Veh). Males were
identiﬁed by visual inspection (ano-genital distance) and this
was then conﬁrmed by PCR for the SRY gene (forward primer
ATC TTC AAG GCG CTG CAA; reverse primer CGG TGG
ACC CTG AGA TTG). Male fetal liver samples were collected
and snap-frozen on dry ice and stored at ¡80C. All remaining
females (5 Dex and 7 Veh) were allowed to deliver their pups
naturally between e21.5 and e23.5. Litters were killed back to 8
per litter, retaining similar numbers of both sexes. At 28 days,
males were sacriﬁced by decapitation following CO2 asphyxia-
tion. Liver was harvested, snap frozen on dry ice, and stored at
¡80C.
Extraction of DNA and RNA samples
Genomic DNA and total RNA samples were extracted using
Qiagen DNeasy and RNeasy kits (Qiagen, Crawley, UK) follow-
ing the manufacturer’s instructions. Both DNA and RNA sam-
ples were quantiﬁed using Qubit (Life Technologies Ltd,
Paisley, UK) and the integrity of DNA and RNA samples were
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analyzed by gel electrophoresis and Agilent Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA, USA).
Illumina RatRef-12 expression BeadChip array
For 3 males per group from separate litters at e20, we under-
took microarray proﬁling of gene expression in fetal liver. RNA
labeling was performed on RNA (500 ng) using the Illumina®
Total Prep RNA ampliﬁcation kit (Life Technologies, Paisley,
UK) and subsequently hybridized to Illumina RatRef-12
expression BeadChip arrays as per the manufacturer’s instruc-
tions at the Wellcome Trust Clinical Research Facility, Genetics
Core, Western General Hospital, Edinburgh, UK.
Expression analysis by RT qPCR
RNA (500 ng) was reverse transcribed for both e20 and 4 weeks
postnatal samples (e20: 8 biological replicates per group from 8
Dex and 8 Veh litters; 4 weeks: 6 biological replicates per group
from 5 Dex and 6 Veh litters) using the Promega Reverse Tran-
scription kit (Promega, Southampton, UK) and real time PCR
was performed using the UPL system from Roche Diagnostics
Ltd., using a Roche Lightcycler 480 (Roche, West Sussex, UK).
Primers were designed using Roche Universal Probe Library
Assays (Roche, West Sussex, UK) and details are given in
Table 1. Gene expression was normalized to the expression of
GAPDH (e20) or the mean of Pgk1 and YWHAZ (4 weeks).
DNA methylation analysis by bisulﬁte pyrosequencing
Genomic DNA (1mg) was subjected to bisulﬁte treatment using
the EZ-DNA methylation kit (Zymo Research, Irvine, CA,
USA) for both e20 and 4 weeks postnatal samples (e20: 8 bio-
logical replicates per group from 8 Dex and 8 Veh litters; 4
weeks: 8 biological replicates per group from 5 Dex and 7 Veh
litters). Loci of interest were ampliﬁed using Pyrosequencing
primers (Table 1) designed using PyroMark Assay design 2.0
software (Qiagen, Crawley, UK). Data were analyzed using
PyroMark 24 software (Qiagen, Crawley, UK).
Heme measurement
Total liver heme was quantiﬁed using a QuantiChromTM
Heme Assay kit (DIHM-250) (BioAssay Systems, CA, USA) for
both e20 and 4 weeks postnatal samples (e20: 8 biological repli-
cates per group from 8 Dex and 8 Veh litters; 4 weeks: 8 biolog-
ical replicates per group from 5 Dex and 7 Veh litters). About
30 mg of liver was homogenized in 500 ml of buffer containing
100 mM K2HPO4 pH7.4 and 2 mM MgCl2. Five times diluted
homogenate was used for measuring heme, following the man-
ufacturer’s protocol. The values were normalized to total pro-
tein content measured using the Bradford assay (BIO-RAD,
Hemel Hempstead, UK).
Data and statistical analysis
Microarray data were read and processed with the Bioconduc-
tor suite.27 The Lumi package 28 was used for preprocessing,
applying a background correction based on control probes
prior to quantile normalization. Differential expression was
assessed with a combination of fold change and a rank product
false discovery rate.29 Gene expression, site-speciﬁc DNA meth-
ylation and heme concentrations were analyzed by independent
Student t testing. Data are expressed as mean § SEM.
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